Video

Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer VL

Search

Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore Details Neal Shores joins Alicia Morgans in conversation to discuss the RALU study. RALU is a retrospective analysis that sought to evaluate the safety and clinical outcomes of sequential radium-223/177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study found that patients tolerated Lutetium-177 well, and PSA and alkaline phosphatase declines were observed....
The Association Between the Time Interval Between Sequential Treatment With Radium-223 Therapy and 177Lu-PSMA in the RALU Study - Kambiz Rahbar Details Kambiz Rahbar joins Alicia Morgans to discuss a post hoc analysis of the RALU study, which looks at the time interval between radium and lutetium-PSMA treatment and its effect on the safety and effectiveness of lutetium treatment in patients with metastatic castration-resistant prostate cancer. This analysis aimed to assess the safety and survival outcomes with lutetium when treatment began within...
Sequencing Radiopharmaceuticals: Efficacy and Safety Data of Radium-223 Followed by Lutetium-177-PSMA in the RALU Study - Oliver Sartor Details In this conversation, Alicia Morgans and Oliver Sartor discuss the safety and efficacy data from the RALU study where patients with metastatic castration-resistant prostate cancer received lutetium-177-prostate-specific membrane antigen (PSMA) with prior radium-223 treatment. The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-p...
Radiopharmaceuticals in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans Details In this conversation, Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 78-year-old man who in 2017, imaging demonstrated numerous bone mets and the patient was subsequently diagnosed with metastatic castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. Drs Shore, Koo, and Morgans talk through treatment options for this patient and the consideration o...
Optimal Treatment Sequencing with Radiopharmaceuticals After Radium-223 in Men with Newly Progressed Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans Details In this conversation, Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 63-year-old man who was diagnosed with de novo metastatic prostate cancer in January 2020. He was initially treated for metastatic hormone-sensitive prostate cancer with enzalutamide plus ADT. He presents again now with progression of bone-only metastatic disease. Drs Shore, Koo, and Morgans talk through...
Sequencing of Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata Details In this conversation, Pedro Barata and Alicia Morgans discuss the sequencing of radiopharmaceuticals in metastatic castration-resistant prostate cancer. Reviewing several trials in this treatment landscape, including data from ALSYMPCA, VISION, REASSURE, WARMTH, and more recently, the RALU study Pedro Barata presents several different treatment scenarios where we can fit radium-223, among all of t...
223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Zachary Klaassen Details In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...